MustGrow Biologics (DE:0C0)
FRANKFURT:0C0
0C0 Stock Chart & Stats
€0.33
-€0.13(-11.93%)
At close: 4:00 PM EST
€0.33
-€0.13(-11.93%)
Day’s Range― - ―
52-Week Range€0.25 - €0.59
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
€16.27M
Enterprise Value€26.32M
Total Cash (Recent Filing)€419.58K
Total Debt (Recent Filing)€553.41K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume1,312
30 Day Avg. Volume1,447
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€15.68M
Bulls Say, Bears Say
Bulls Say
Moderate LeverageA debt-to-equity around 0.67 indicates leverage is not extreme, which gives MustGrow more financial flexibility than highly leveraged peers. Over 2–6 months this reduces immediate solvency pressure and preserves optionality for funding product development or partnerships without imminent default risk.
Focused Biologics NicheA clear focus on mustard-seed derived biologics and soil-health products creates a durable strategic niche. Specialization supports IP development, regulatory expertise, and differentiated product positioning that can build long-term customer relationships and partnership channels in the agricultural inputs market.
Demonstrated Revenue AbilityHistorical periods of meaningful revenue (including stronger scale in 2025) show MustGrow can commercialize products and access farmer/end-user demand. This operational capability is a durable asset: it lowers execution risk versus pre-revenue peers and supports potential revenue recovery if product-market fit and distribution are sustained.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow erode runway and make the business reliant on external financing. Over a multi-month horizon this constrains strategic choices, increases dilution or debt risk, and limits the ability to scale commercial efforts or fund regulatory and R&D milestones independently.
Deep Negative ProfitabilityVery large negative EBIT and net margins indicate the current cost structure and pricing do not support profitable operations. Persistently wide losses reduce internal capital generation, hinder reinvestment, and make long-term viability dependent on structural improvements to margins or sustained external funding.
Eroded Equity And ReturnsSharp equity erosion and massively negative ROE weaken the balance sheet's capacity to absorb shocks and restrict borrowing or partnership leverage. Over months this increases the likelihood of further dilution or constraints on growth investments, and reduces creditor and investor tolerance for ongoing losses.
MustGrow Biologics News
0C0 FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was €0.25 and its highest was €0.59 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is €16.27M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 61 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in DE:0C0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
0C0 Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---